Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGR | P06401 | 16/20 | 0.60 |
| ▸ | AR | P10275 | 5/20 | 0.60 |
| ▸ | CYP2D6 | P10635 | 10/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 10/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.43 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.43 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.43 |
| ▸ | POLQ | O75417 | 1/20 | 0.43 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4595409 | 1.00 | PGR (0.60) | PGRARCYP2D6CYP2C9CYP2C19 | |
| SCHEMBL4595879 | 0.90 | PGR (0.76) | PGRARCYP2D6CYP2C9CYP2C19 | |
| SCHEMBL4595878 | 0.90 | PGR (0.76) | PGRARCYP2D6CYP2C9CYP2C19 | |
| SCHEMBL4903805 | 0.87 | PGR (0.55) | PGRARCYP2D6CYP2C9CYP2C19 | |
| SCHEMBL4903803 | 0.87 | PGR (0.55) | PGRARCYP2D6CYP2C9CYP2C19 | |
| SCHEMBL3296555 | 0.85 | AR (0.79) | PGRARS1PR1 | |
| SCHEMBL3296551 | 0.85 | AR (0.79) | PGRARS1PR1 | |
| SCHEMBL4594559 | 0.85 | PGR (0.65) | PGRARCYP2D6CYP2C9CYP2C19 | |
| SCHEMBL3288098 | 0.84 | AR (0.63) | PGRARS1PR1 | |
| SCHEMBL3288101 | 0.84 | AR (0.63) | PGRARS1PR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080194536-A1 | Cyanoarylamines | SMITHKLINE BEECHAM CORPORATION | 2008-08-14 | — | — | US | disclosed |
| EP-1871379-A2 | CYANOARYLAMINES | Smithkline Beecham Corporation (US) | 2008-01-02 | — | — | EP | disclosed |
| WO-2006113552-A2 | CYANOARYLAMINES | SMITHKLINE BEECHAM CORPORATION (US) | 2006-10-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080194536-A1 | Cyanoarylamines | EDNRA, CYP19A1, HSD17B11 | PGR 64/4885AR 84/4885CYP2D6 622/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.